IP Library › Granted Patent US 9,834,758
Granted Patent B2
US 9,834,758 · App. 14/755,056 · Granted Dec 5, 2017

Ketoreductase polypeptides for the preparation of phenylephrine

Inventors: Oscar Alvizo (Fremont, CA); Steven J. Collier (Concord, MA); Hans-Georg Joerg Hennemann (Bedburg, DE); Seong Ho Oh (Singapore, SG); Wenjuan Zha (Singapore, SG)
Assignee: Codexis, Inc.
C12N9/0006A61K31/137C12P13/001C12Y101/01184
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,834,758
App. No.
14/755,056
Granted
Dec 5, 2017
Kind
B2
Abstract

The disclosure relates to engineered ketoreductase polypeptides and processes of using the polypeptides for production of phenylephrine.

Claims (14)

1. An engineered polynucleotide sequence encoding an engineered polypeptide capable of converting 1-(3-hydroxyphenyl)-2-(methylamino)ethanone to (R)-phenylephrine, wherein the amino acid sequence of the polypeptide has at least 95% identity to SEQ ID NO: 4 and comprises the residue difference A202F.

2. The engineered polynucleotide of claim 1 , wherein the amino acid sequence further comprises the residue difference M206C.

3. The engineered polynucleotide of claim 1 , wherein the amino acid sequence comprises at least two further residue differences selected from V95M, S96L, L147I, and C190G.

4. The engineered polynucleotide of claim 1 , wherein the amino acid sequence further comprises the residue differences: V95M, and M206C.

5. The engineered polynucleotide of claim 1 , wherein the amino acid sequence further comprises the residue differences: V95M, C190G, and M206C.

6. The engineered polynucleotide of claim 1 , wherein the amino acid sequence further comprises the residue differences: V95M, C190G, M206C, and Y249F.

7. The engineered polynucleotide of claim 1 , wherein the amino acid sequence further comprises at least one residue difference selected from T2S, II1L, A64V, T76I, V95M, S96L, V99L, V148L, T152A, L153M, S159T, D197A, and E200P.

8. The engineered polynucleotide of claim 1 , wherein the polypeptide is capable of stereospecifically converting 1-(3-hydroxyphenyl)-2-(methylamino)ethanone to (R)-phenylephrine in a enantiomeric excess of at least 99%.

9. The engineered polynucleotide of claim 1 , wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 20, 26, 28, 30, 32, and 34.

10. The engineered polynucleotide of claim 1 , wherein the amino acid sequence of the polypeptide further comprises at least one residue difference selected from T2, 111, A64, T76, V95, V99, V148, T152, L153, S159, D197, or E200, wherein said residues are numbered with reference to SEQ ID NO: 4.

11. An expression vector comprising the engineered polynucleotide of claim 1 .

12. The expression vector of claim 11 , operably linked to a control sequence suitable for directing expression in a host cell.

13. A host cell comprising the expression vector of claim 11 .

14. A host cell comprising the expression vector of claim 12 .

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (3)
Division 13390677
Provisional Application 61235324 · Aug 19, 2009
Related Publication 20150299671A1 · Oct 22, 2015